Articles from X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder -
By X4 Pharmaceuticals, Inc. · Via GlobeNewswire · February 27, 2026